序号 |
标题 |
次数 |
作者 |
发布时间 |
75736 |
金属螯合剂DOTA偶联α-MSH八肽类似物 |
64 |
h |
2024-12-19 |
75737 |
cas:1286715-33-0,2,5-Dioxopyrrolidin-1-yl 4-methyl-4-((2-methyl-5-oxo-5-(2-(trimethylsilyl)ethoxy)pentan-2-yl)disulfanyl)pentanoate |
103 |
kx |
2024-12-19 |
75738 |
DOTA-conjugated multivalent cyclic-RGD DOTA-共轭多价环RGD肽树枝状大分子 |
74 |
h |
2024-12-19 |
75739 |
Azidoethyl-SS-ethylazide CAS:352305-38-5 |
80 |
zyl |
2024-12-19 |
75740 |
CAS: 870487-09-5, Boc-Val-Cit-PAB |
78 |
WYQ |
2024-12-19 |
75741 |
cas:2101206-67-9,Ald-Ph-amido-PEG1-C2-Pfp ester, ADC试剂 |
71 |
kx |
2024-12-19 |
75742 |
Ald-Ph-amido-PEG11-NH-Boc CAS:1245813-70-0 |
101 |
zyl |
2024-12-19 |
75743 |
HSA-2-iminothiolane-DOTA HSA-2-亚氨基硫醇-DOTA |
91 |
h |
2024-12-19 |
75744 |
cas:1222787-24-7,2,5-Dioxopyrrolidin-1-yl 4-((2-((2-(2-(4-(2,6-dioxo-1,3-dipropyl-2,3,6,9-tetrahydro-1H-purin-8-yl)phenoxy)acetamido)ethyl)amino)ethyl)disulfanyl)-4-oxobutanoate |
203 |
kx |
2024-12-19 |
75745 |
Tr-PEG5-OH CAS:141282-24-8物理化学性质 |
96 |
zyl |
2024-12-19 |
75746 |
CAS: 870487-08-4,Boc-Val-Cit,(S)-2-((S)-2-((叔丁氧基羰基)氨基)-3-甲基丁酰胺基)-5-脲基戊酸 |
96 |
WYQ |
2024-12-19 |
75747 |
DOTA-8-Aoc-BBN[7-14]NH |
106 |
h |
2024-12-19 |
75748 |
Fmoc-PEG3-Val-Cit,N-Fluorenylmethoxycarbonyl-triethylene glycol-Val-Cit |
82 |
WYQ |
2024-12-19 |
75749 |
CAS: 2226472-28-0,DBCO-PEG4-Val-Cit-PAB-PNP |
78 |
WYQ |
2024-12-19 |
75750 |
CAS: 2055024-64-9,Azido-PEG4-Val-Cit-PAB-OH |
83 |
WYQ |
2024-12-19 |
75751 |
CAS: 870487-09-5,Boc-Val-Cit-PAB |
84 |
WYQ |
2024-12-19 |
75752 |
CAS:784105-33-5 Amino-PEG3-C2-acid的介绍 |
74 |
zyl |
2024-12-19 |
75753 |
CAS 863971-53-3:Fmoc-Val-Cit-PAB-PNP |
88 |
WYQ |
2024-12-19 |
75754 |
Ald-Ph-amido-PEG11-C2-NH2 CAS:1337889-01-6 |
71 |
zyl |
2024-12-19 |
75755 |
cas:2003260-13-5 , MA-PEG4-Ala-Ala-PAB-PNP,ADC定制 |
74 |
wyh |
2024-12-19 |
75756 |
DOTA-NCS-6-Ahx-Phe 19-ST[1-19] DOTA偶联ST肽类似物 |
102 |
h |
2024-12-19 |
75757 |
1,4,7,10-四氮杂-n-(1-羧基-3-(4-硝基苯基)丙基)-n,N , N ‴-tris(acetic酸)环十二烷(PA-DOTA) |
69 |
h |
2024-12-19 |
75758 |
CAS 159858-22-7:Fmoc-Val-Cit-PAB-OH |
61 |
WYQ |
2024-12-19 |
75759 |
cas:5117-19-1,Octanethyl glycol ,八乙二醇的主要特点 |
100 |
zyl |
2024-12-19 |
75760 |
CAS 159857-79-1:Val-Cit-PAB-OH,缬氨酸(Val)、琥珀酰亚胺(Cit)和对氨基苯甲酸(PAB)的衍生物 |
110 |
WYQ |
2024-12-19 |
75761 |
SPDP-Val-Cit-PAB-OH,ADC定制 |
69 |
wyh |
2024-12-19 |
75762 |
DOTA-LVT 螯合剂DOTA偶联Lys8-血管收缩素 |
101 |
h |
2024-12-19 |
75763 |
cas:2054345-67-2,azido-tris(ethylenoxy)-L-alanine TFA Salt化学性质 |
83 |
zyl |
2024-12-19 |
75764 |
cas:68617-64-1,SPDP acid,3-(2-吡啶二硫代)丙酸的合成方法 |
120 |
zyl |
2024-12-19 |
75765 |
1,4,7,10-四(羧甲基)-1,4,7,10-四氮杂环十二烷单酰胺偶联葡萄糖 |
85 |
h |
2024-12-19 |
75766 |
PEG-P(Asp-Gd-DOTA)Gd‐DOTA偶联聚乙二醇改性聚天冬氨酸 |
91 |
h |
2024-12-19 |
75767 |
cas:70539-42-3,EGS Crosslinker,乙二醇-双(琥珀酸N-羟基琥珀酰亚胺酯)的结构式 |
143 |
zyl |
2024-12-19 |
75768 |
CXCR4导向的五肽[(68)Ga]喷替沙福(环(-D-Tyr-N-Me-D-Orn(AMB-DOTA)-L-Arg-L-2-Nal-Gly-)) |
125 |
h |
2024-12-19 |
75769 |
α-hexadecyl-DOTA α-十六烷基-DOTA |
85 |
h |
2024-12-19 |
75770 |
Methyltetrazine-SS-NHS 甲基四唑-双硫键-活性酯的合成方法 |
76 |
zyl |
2024-12-19 |
75771 |
DOTA-AgRP-6E |
112 |
h |
2024-12-19 |
75772 |
DOTA-morab-003 DOTA偶联单克隆抗体MORAb-003 |
76 |
h |
2024-12-19 |
75773 |
DOTA-Bz-folate DOTA-Bz-叶酸 |
93 |
h |
2024-12-19 |
75774 |
cas:55750-53-3,6-Maleimidocaproic acid,6-马来酰亚氨基己酸 |
107 |
zyl |
2024-12-19 |
75775 |
cas: Fmoc-PEG3-Val-Cit,ADC定制 |
88 |
wyh |
2024-12-19 |
75776 |
钆(III)DOTA-DSPE脂质体 |
81 |
h |
2024-12-19 |
75777 |
CAS: 870487-08-4,Boc-Val-Cit,叔丁氧羰基-缬氨酰-L-瓜氨酸 |
72 |
WYQ |
2024-12-19 |
75778 |
DOTA-Phe-D-Trp-Lys-Thr-OMe DOTA偶联生长抑素四肽类似物 |
106 |
h |
2024-12-19 |
75779 |
CAS: 35665-38-4,Fmoc-Gly-Gly-OH,Fmoc-甘氨酰-甘氨酸 |
108 |
WYQ |
2024-12-19 |
75780 |
cas:117235-10-6,3-Mercaptopropanyl-N-hydroxysuccinimide ester的结构式 |
107 |
zyl |
2024-12-19 |